Clinical TrialID 5657

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

NCT01703078

Actinic Keratosis

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5657
Evidence Id
5657
Core Evidence Id
5657
Source Clinical Trial Id
5643
Herb2 Clinical Trial Id
HBCT005643
Nct Id
NCT01703078
Title
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
Status
Completed
Phase
Phase 1
Study Result
No
Study Condition
Actinic Keratosis
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
Intervention
DRUG: Ingenol once daily for two consecutive days
Intervention Allocation
Randomized
Intervention Model
Single_Group
Intervention Mask
Single
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
41
Outcome Measure
Safety of a new ingenol derivative compared to ingenol mebutate gel applied topically once daily for two consecutive days to four separate treatment areas containing actinic keratosis on the forearm, Safety data to be collected via CRF entries of AEs/SAEs and photographs., 8 weeks
Sponsor Collaborator
LEO Pharma
Funded By
INDUSTRY
Location
Dermatology Department, Woolloongabba, Queensland, 4102, Australia
Other Id
LP0084-68
Start Date
2012-11
Primary Completion Date
2013-03
Completion Date
2013-04
First Posted
2012-10-10
Results First Posted
Last Update Posted
2013-04-04
Study Document
Study Url
https://clinicaltrials.gov/study/NCT01703078
Title Cn
Title En
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
Bilingual Status
semi_complete